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Abstract
Anatomo-clinical studies of the neuroendocrine tumors of the stomach only can be well 
completed with a view of the basic characteristics of the elements of the so-called neuro-
endocrine system or gastrointestinal APUD system. Therefore, these gastric neoplasias 
cannot be studied in isolation because they are derived from a special line of endocrine 
cells that have many common biochemical bonds which are often involved in the clinical 
behavior of the tumor. These cells are called “APUD” for their biochemical and morpho-
logical characteristics, and their tumors as “apudomas.” APUD cells store amines and 
regulatory peptides and are dispersed throughout the body and concentrated mainly 
in the digestive tract. Other names used for tumors of the same cell line, namely, “carci-
noids,” “endocrine tumors,” and “neuroendocrine tumors,” are not yet very well defined, 
although they are ostensibly used. The gastric apudomas do not escape of the basic rules 
of behavior of their counterparts of other sites of the digestive tract. Nevertheless, most of 
them present peculiar pathogenetic and pathophysiological characteristics whose knowl-
edge is important to better understand the patient with this type of lesion.
Keywords: neuroendocrine tumors, gastric apudomas, gastric carcinoids, atrophic body 
gastritis, APUD cells
1. Introduction
Gastrointestinal neuroendocrine tumors make up a group of heterogeneous neoplasms of 
somewhat unpredictable biological and clinical behavior. These tumors arise mainly in the 
digestive tract but can occur in other organs that harbor neuroendocrine cells. They are con-
sidered complex tumors and of unpredictable clinical evolution due to the variety of attri-
butes that they possess as the potential capacity of secretion of a large variety of peptides.
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Although they may appear benign tumors for a certain period of time, they can originate tis-
sue infiltration and give metastasis. All these pathophysiological attributes of neuroendocrine 
tumors, which may occur in varying degrees of intensity in different patients, arouse general 
interest, and so they are studied by professionals from different expertise. In this chapter, we 
will turn to the study of some relevant aspects of these tumors that originate in the stomach. 
However, since these neoplasias are part of a large family of gastrointestinal tumors, we will 
carry out a summary review of the main attributes of this family which should be useful to 
better understand some nuances of these tumors which originate in the stomach.
2. General aspects of neuroendocrine gastrointestinal system
The terms “neuroendocrine tumors,” “carcinoid tumors,” and “endocrine tumors” are widely 
used when referring to tumors of the digestive tract. These designations can be found simul-
taneously even as part of the same classification. Neuroendocrine tumors were firstly called as 
“carcinoid tumors” by the German pathologist Oberndorfer, in 1907 [1]. And until now, the term 
carcinoid has been used ostensibly, colloquially, and even in almost all current classifications [2, 3].
The term “apudoma” may also be considered as being a synonym of carcinoid tumor. The 
denomination of “APUD cells” was proposed by Pearse in the late 1960s as an acronym of 
amine precursor uptake and decarboxylation [4]. The term APUD summarizes some of the most 
important characteristics of these cells, which are (a) a high amine content and/or amine pre-
cursor uptake, (b) amino acid decarboxylase activity, and (c) characteristic ultrastructural 
pattern. Initially, the term “apudoma” was used mainly from the clinical point of view to 
designate those tumors of symptomatic patients due to the pathological secretion of bioac-
tive products and afterward also for clinically asymptomatic tumors originating from APUD 
cells [5–7]. As we can see, unlike the roots of the other designations for these tumors, the term 
“apudoma” has been derived from consistent morphologic and biochemical basis.
Apudomas are derived from the APUD cell line and so they have characteristic ultrastruc-
tural pattern recognized due the presence in the tumor cells of secretory granules where 
the regulatory peptides are located as well as the biogenic amines that they produce [8, 9]. 
Normally, the APUD cells are rich in amino acid decarboxylase, which gives them the abil-
ity to capture 5-hydroxytryptophan and dihydroxyphenylalanine and produce, respectively, 
serotonin and dopamine. Although this property has not been demonstrated in all the cells 
morphologically characteristic of this system, this biochemical link may occur in all of them 
whatever their specific function is. This gives these cells a familial, morphological, and bio-
chemical bond, which extends to a greater or lesser degree to the apudomas. In addition, 
these morphological and biochemical characteristics give to the term “APUD” a biologically 
more specific designation compared to the other denominations. Thus, the term “apudoma” 
is less vulnerable to temporal changes than those currently used, namely, “carcinoid,” 
“endocrine tumor,” and “neuroendocrine tumor.” The latter denomination is being adopted 
in this article because of its extensive use in modern classifications and also throughout the 
medical literature indexing.
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2.1. Tumor sites and staining
One of the first steps, both in pathology and clinics, when we are faced with the possibility 
to do the diagnosis of a gastrointestinal apudoma, is the knowledge of its possible primary 
 location (Table 1). It may seem like an unimportant detail, but this can be very valuable as a 
first step to better understand the biology of the tumor [10, 11].
Sometimes, we deal with an unknown primary site metastasis. But knowing which segment 
of the digestive tract derives the tumor may be helpful because this information gives an idea 
on the possible evolution of the apudoma. Regarding the gastric apudomas, this is a crucial 
knowledge as we will see later on. In addition, the pathologist gains confidence in the study 
of the diagnostic possibilities, including for the evaluation which stain techniques or which 
neuroendocrine marker should be used [12]. Most of the gastric apudomas do not produce 
serotonin and are negative for argentaffin staining; on the other hand, they usually are posi-
tive for argyrophilic and chromogranin staining (Figure 1). These properties of apudoma, in 
relation to certain staining techniques, often depend on their place of origin (Table 2) [13–15].
Currently, immunohistochemistry techniques have been used as tools of choice for the specific 
histologic diagnosis of apudomas. Through this methodology, it is sought to mark the presence 
of antigenic products typical of APUD cells and also frequently present in apudomas (Figures 2 
and 3). Neuron-specific enolase (NSE) was the first immunohistochemical marker for histological 
diagnosis of apudomas [16]. Before the discovery of this marker, the most commonly available 
methods were silver staining. Synaptophysin is also a neuroendocrine marker, located on the 
membrane of the synaptic vesicles, and present in neurons, neuroendocrine cells and in many 
neuroendocrine tumors [17, 18]. Chromogranins comprise a group of acidic polypeptides that 
make up about 40–50% of the soluble protein content of the suprarenal medullar granules. The 
chromogranin A is the most widespread; it is present in varying amounts in the secretion gran-
ules of neuroendocrine cells and in neuroendocrine tumors [15, 18]. If the tumor is less differenti-
ated and with fewer secretory granules in the cytoplasm, the staining can give doubtful results or 
even a false-negative reaction. Chromogranin is one of the main markers used for the histological 
diagnosis of gastric apudomas presenting high index of sensitivity and specificity. It is also tenta-
tively used as a serologic marker of apudoma evolution [19]. It is always appropriate to remem-
ber that the antibodies used against apudoma antigens are derived from different clones and are 
provided by different companies. This may result in differences in sensitivity and specificity of 
each set of reagents, and these different properties must be under the control of each laboratory.
Foregut Midgut Hindgut
Esophagus Jejunum/ileum Distal colon
Stomach Appendix Rectosigmoid
Duodenum Cecum
Apudomas can arise in any region of the gastrointestinal tract. These regions are known as foregut, midgut, and hindgut. 
Apudomas from these different sites frequently present different clinical behaviors.
Table 1. Primary sites of the gastrointestinal apudomas.
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2.2. General view on pathology of gastrointestinal apudomas
We have now reached a point which concerns more directly the attending physician. Since the 
apudomas frequently present unpredictable clinical evolution, how could the histopathology 
help on this matter? In fact, all the factors shown in Table 3 are important to evaluate the pos-
sible clinical behavior of a given gastrointestinal apudoma. However, the two first, i.e., degree 
Figure 2. Some of the neuroendocrine markers are scattered in the cytoplasm of apudoma cells such as PGP 9.5, 
synaptophysin, and neuron specific enolase. Chromogranin and the regulatory peptides are stored in secretory granules. 
The amount of these granules in the neoplastic cells will determine weaker or stronger staining of the tumor.
Gastrointestinal apudomas and silver staining properties
Foregut Midgut Hindgut
Argyrophilic tumors +++ +++ ++
Argentaffin tumors + +++ +
+, seldomly positive; ++, sometimes negative; +++, much frequently positive
Table 2. Almost all the gastric apudomas are demonstrated by argyrophilic staining and/or by argentaffin methods.
Figure 1. Although it is nonspecific staining for APUD cells and apudomas, the argentaffin and argyrophilic stains may 
be useful for the demonstration of these elements [13].
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of histologic tumor differentiation and the proliferative activity of the neoplastic cells, depend 
exclusively on the pathologist interpretation. And unlikely, the last four parameters shown in 
Table 3 depend on the opinion of different expert professionals to reach more reliable conclu-
sions about the clinical course of the tumor.
In general pathology, the degree of differentiation of a given epithelial tumor, evaluated by his-
tology, has always been, and still is, a criterion that together with other ones, gives an idea about 
the grade of malignancy that a particular carcinoma must have: a less aggressive evolution, more 
common among the well-differentiated ones, or a more aggressive evolution more common in 
those poorly differentiated (Figure 4). This histopathological criterion continues to be applied 
Figure 3. (A) G cell of the gastric mucosa stained specifically with antibody against gastrin. The staining is very specific 
by observing that the background elements, i.e., other cells and surrounding tissues, are completely negative. The very 
strong contrast between the positive and negative elements of tissue confers confidence of the final result in relation 
to the specificity of the staining reaction. (B) The staining contrast is not always very clear in regard to apudomas 
which may exhibit cells with various degrees of differentiation. A variable number of neoplastic cells with low secretory 
granule density could present a dubious or completely negative reaction. As a result, a given gastrinoma may exhibit 
cells strongly reactive to the gastrin antibody alongside others completely negative.
Table 3. Main criteria to determine the malignant potential of the apudoma.
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mainly in relation to the nonendocrine carcinomas. Concerning the apudomas, this parameter, 
as an isolated element, has little value. Differently, the well-differentiated apudoma can present 
unpredictable clinical behavior. However, when the tumor is histologically poorly differenti-
ated, the prognosis is often worse. In this respect, this criterion of cellular differentiation may be 
helpful. In addition, apudomas present varying densities of membrane receptors for different 
regulatory peptides, including somatostatin. And, a high density of these receptors in apudoma 
cells acquires current medical importance for the patient treatment. Some data indicate that the 
somatostatin receptor density would be dependent on the degree of tumor grade [20].
Under the view of histopathological diagnosis, the malignancy potential of a particular apudoma 
rests mainly on the degree of tumor cell proliferation. This criterion can be applied to all apudo-
mas regardless of their origin. There are two histopathological tools to assess the degree of cell 
proliferation: (i) the number of observable mitoses in the routine preparations stained by hema-
toxylin and eosin and (ii) the index of cell immunoreactivity for Ki-67 antibody. The Ki-67 reactive 
protein is only expressed in the nucleus of cells that are in the various phases of the active cell 
replication cycle. This protein is not expressed in resting cells, that is, the cells that have not yet 
entered the active mitotic cycle. Moreover, there is not always any correspondence between the 
degree of differentiation of a given apudoma and the degree of cell proliferation [21, 22].
Concerning proliferative activity, the low-grade (G1) tumors present very few numbers of 
mitosis in routine HE preparation or otherwise less than 3% of neoplastic cells stained by 
Ki-67 antibody. The high-grade (G3) tumors should present more than 20 mitoses per 10 
microscopic high-power field (hpf) or more than 20% of the neoplastic cells positive to Ki-67 
antibody. Finally, tumors with intermediate degree of cell proliferation that lie between these 
two extremes are considered to be G2.
2.3. Gastric apudomas
Almost all apudomas of the stomach are derived from the endocrine cells of the body mucosa 
and rarely from the endocrine cells of the antral mucosa. They represent approximately 2–4% 
of all gastric neoplasias and 7.2% of all apudomas of the gastrointestinal tract [10].
Figure 4. Well-differentiated type 1 (A) and poorly differentiated type 2 (B) gastric apudomas. Although the degree of 
tumor differentiated could have some importance regarding the degree of malignancy, the proliferative activity remains 
as a better histopathological indicator for this purpose.
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In recent decades, there has been evidence that favors believing in an increase in the incidence 
of gastric apudomas. To a great extent, this increase must be occurring due to the  technological 
evolution of the instruments connected to endoscopy of the upper digestive tract because 
these tumors are mostly often discovered incidentally during endoscopy. However, a real 
increase in the prevalence of these tumors cannot be ruled out [11, 23, 24].
The apudomas of the stomach are generally divided into three different groups based on their 
clinical and physiopathological characteristics: type 1, apudomas of the stomach associated 
with atrophic body gastritis (ABG), with or without pernicious anemia; type 2, apudomas 
of the stomach associated with Zollinger-Ellison syndrome, sporadic or familial; and type 3, 
sporadic apudoma not associated with known predisposing disease [25].
2.4. Gastric apudoma type 1
These are the most frequent gastric neuroendocrine tumors. They are characteristically associ-
ated with atrophic body gastritis (ABG) and are the most frequent of the gastric apudomas 
constituting about 70–80% of them. The criterion adopted for the classification of these tumors 
in type 1 is the recognition of the presence of established chronic autoimmune gastritis, with 
or without pernicious anemia, or just the presence of atrophic body gastritis confirmed by 
histopathology. This type of tumor appears to be more prevalent in women as well as the 
prevalence of the underlying disease (Figure 5).
Therefore, it can be assumed that this type of tumor is a direct consequence of the atrophic body 
gastritis. According to this diagnostic criterion, we can conclude that the different types of apu-
domas of the stomach cannot be diagnosed based only on their endoscopic and histopathological 
pattern. Therefore, for the inclusion or exclusion of a gastric apudoma as type 1, it is necessary 
that in addition to histological samples of the tumor itself we also have samples of the gastric 
mucosa of the antral and body regions of the stomach to confirm or rule out the possibility of 
atrophic body gastritis. Recognizing an endocrine tumor as type 1 opens a range of possibilities 
to better understand the set of pathophysiological changes that may be occurring in the patient:
Figure 5. Distribution of 196 consecutive patients with atrophic body gastritis according to the age and gender. Patients 
were from a general hospital in Belo Horizonte, Brazil [26].
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a. Gastric apudoma type 1 occurs in the mucosa of the fundus or the gastric body generally 
as multiple nodules, smaller than 1 cm in most cases. As they are generally multiple, they 
may occur according to an irregular distribution in the gastric body, the gastric fundus, 
or in the two regions simultaneously (Table 4). Usually, these nodules are projected into 
the lumen of the stomach and are frequently diagnosed by endoscopy as “gastric polyps.” 
This diagnosis is not always incorrect because in ABG hyperplastic polyps are relatively 
frequent.
b. The neoplasia usually consists of well-differentiated neuroendocrine cells with a low Ki-
67 index (G1) indicating low levels of cell proliferation. This characteristic is in agreement 
with the indolent evolution of these tumors; only a small number of them present metas-
tases when diagnosed and rarely take the patient to death (Table 4).
c. Due to atrophy of the oxyntic mucosa these patients present hypochlorhydria or 
achlorhydria.
d. Since the gastric mucosa of the corpus is atrophic and the antral mucosa is preserved, the 
G cells are usually hyperfunctioning, and these patients frequently present hypergastrine-
mia (Table 4 and Figure 6).
e. Even without the occurrence of high levels of serum gastrin, the constant trophic stimuli 
of this hormone will lead to hyperplasia of the endocrine cells of the gastric body. These 
hyperplastic cells are believed to be enterochromaffin-like (ECL) cells. However, other 
types of neuroendocrine cells may be participating in this hyperplastic process, includ-
ing ghrelin-producing cells [26]. The areas of neuroendocrine cell hyperplasia can be 
found in almost all cases of well-established atrophic body gastritis (Figures 7–9). As we 
have already said, these areas of endocrine hyperplasia occur along the atrophic mucosa 
and according to their morphological aspect can be classified as (i) diffuse, (ii) linear, and 
(iii) nodular [27].
f. Based on these general aspects of atrophic body gastritis, it is possible to conclude that the 
areas of neuroendocrine hyperplasia are probably the precursor lesion of type 1 gastric 
apudoma. However, there are no histological signs that highlight where the hyperpla-
sia ends and where the neoplasm begins. In this regard, the large, confluent hyperplastic 
nodules with a diameter about 300–500 μm associated with infiltration of mucosa tissues 
would already be classified as indicative of emerging neoplastic lesion (Figure 9). Just for 
comparison, 500 μm is equivalent, on average, to half thickness of normal oxyntic mucosa 
in formalin-fixed histologic sections.
g. The infiltration of the submucosa by the hyperplastic endocrine cells is already a sign of 
malignant behavior. However, for the most part, these type 1 gastric apudomas present 
indolent evolution, and few of them present metastasis at the time of diagnosis (Table 4).
2.5. Gastric apudoma type 2
Type 2 gastric apudomas are those associated with sporadic or familial Zollinger-Ellison syn-
drome. They account for only 5–6% of the gastric apudomas. Almost always these tumors 
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Figure 6. Drawing showing the pathogenetic mechanisms of the gastric apudomas type 1 and type 2. The pathophysiological 
central mechanism associated with these two types of tumors is the occurrence of hypergastrinemia or a persistent supra-
basal gastrinemia.
Figure 7. Diffuse and linear types of endocrine cell hyperplasia in atrophic body gastritis. The hyperplastic cells are 
stained for chromogranin.
Type 1 Type 2 Type 3
Frequency (%) 70–80 5–10 10–15
Endoscopic view Multiple and small Multiple and small Single (>2 cm)
Site Gastric body/fundus Gastric body/fundus Any region
Cellular proliferation index G1 G1/G2 G3
Gastrinemia Generally high Generally high Normal
Metastasis (%) 2–5 10–30 50–100
Table 4. Differential profiles between the three groups of gastric apudomas.
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occur in patients with multiple endocrine neoplasia (MEN) type 1. Rarely, there is also a 
Zollinger-Ellison syndrome (ZES) not associated with multiple endocrine neoplasia (MEN) 
which leads to gastric apudoma development. In this case the ZES may be due to the presence 
of a sporadic gastrinoma, the main location of which is believed to be the tail of the pancreas. 
Thus, most frequently, the patient presenting a type 2 gastric apudoma may be a carrier of 
the genetic transmission of MEN syndrome. MEN-1 is an inherited autosomal dominant syn-
drome caused by an inactivating mutation of the MEN-1 gene, which is a tumor suppressor 
gene. MEN-1 syndrome may include the development of primary hyperparathyroidism, pan-
creatic islet tumors, and pituitary adenomas. In addition, some patients may develop other 
neoplasms such as thyroid tumors, adrenal adenomas, pheochromocytomas, and neuroendo-
crine tumors mainly of the gastroduodenal area.
Figure 9. Endocrine cell forming large hyperplastic nodules in the lamina propria. This type of lesions may be indicative 
of an emerging gastric apudoma. As these tumors may be multicentric, it is possible that more strongly suspected lesions 
occur in other areas of the gastric mucosa. Chromogranin staining.
Figure 8. Nodular type of endocrine cell hyperplasia in atrophic body gastritis. The hyperplastic cells form small nodules 
in the lamina propria. Chromogranin staining.
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2.6. Gastric apudoma type 3
Type 3 gastric apudomas are known as sporadic gastric tumors, representing about 10–15% 
of all gastric apudomas, and develop independently hypergastrinemia as well as gastric 
endocrine cell hyperplasia (Table 4). More frequently they present as a single polypoid 
tumor usually greater than 2 cm in size [28]. These tumors are composed mainly by entero-
chromaffin-like cells, and differently from the other gastric apudoma, they have an aggres-
sive clinical evolution. These tumors present histopathological signs corresponding to the 
clinical evolution of worse prognosis such as angioinvasion, rapid growth, mitotic activity, 
and high Ki-67 index.
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